Edwards prioritizes TAVR, TMTT tech in investor day presentation

Edwards Lifesciences (NYSE:EW) today released its strategies for longer-term growth, updated on its technology pipeline and released preliminary financial guidance for the coming fiscal year in its investor day presentation. Edwards lead with news about its transcatheter aortic valve replacement technologies, saying it expects that TAVR opportunity will reach approximately $7 billion by 2024, and that it estimates its TAVR sales next year will be between $2.4 billion and $2.7 billion. The Irvine, Calif.-based company said that it plans to continue investing in TAVR research & development and clinical trials and that it wants to “produce additional transformational TAVR technologies.” Edwards added that it expects to receive a low-risk indication for its existing TAVR tech late next year, with a single-arm trial launch planned for next year exploring the use of TAVR in underrepresented and minority populations. Edwards spoke on its transcatheter mitral and tricuspid therapies, saying it expects the tech to have an estimated opportunity of approximately $3 billion by 2024. The company said it “expects a strong cadence of transformational therapies,” including three TMTT tech devices to be available in Europe next year. The company said it expects to launch its Konect system, featuring a ready-to-implant tissue valve conduit, some time next year in both the U.S. and Europe, with a release of its Harpoon system in Europe by mid-year 2019. It added tha...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Wall Street Beat Edwards Lifesciences Source Type: news